Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene

International Journal of Molecular Sciences(2022)10.3390/ijms232416213Source: DataRank Database

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene is a research paper published in International Journal of Molecular Sciences (2022). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.63)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (25)

Orsola di Martino ORCID,Sabeeha Reshi,Sanchita Mallick,Michael Sausedo,Grant A. Moen ORCID

Live enrichment

PubMed:36555852 PMC:PMC9782500 OpenAlex:https://openalex.org/W4312196641

US National Institutes of Health

Grant: 1 R15 CA139364-01A2

Modeling, Synthesis, and Biological Evaluation of Potential RXT Selective Agonist

NIH HHS

Grant: R01 HL128447

NIH HHS

Grant: 1R15CA249617-01

Assessing Novel Rexinoids Developed by Comparative Bioresponse Analysis in an Innovative Mouse Model of Cutaneous T Cell Lymphoma

NCI NIH HHS

Grant: R15 CA249617

National Institutes of Health

Grant: 5R01HL128447-03

RETINOIDS IN HEMATOPOIESIS

National Institutes of Health

Grant: 5P30CA091842-05

Core--Pharmacology Facility

Siteman Investment Program

FWCI

0.63

Citation Percentile

0.6%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/23/24/16213/pdf?version=1671532686

publisherhttps://www.mdpi.com/1422-0067/23/24/16213/pdf?version=1671532686

journalhttps://doi.org/10.3390/ijms232416213

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36555852

repositoryhttps://digitalcommons.wustl.edu/oa_4/1060

Fields of Study

Retinoids in leukemia and cellular processesUbiquitin and proteasome pathwaysAntioxidant Activity and Oxidative Stress0301 basic medicine03 medical and health sciences

MeSH Terms

Liver X ReceptorsBexaroteneCoumaric AcidsHumansLeukemiaRetinoidsSkin NeoplasmsTetrahydronaphthalenesTriglyceridesLymphoma, T-Cell, CutaneousRetinoid X Receptors

Keywords

BexaroteneRetinoid X receptorChemistryPharmacologyLiver X receptorNuclear receptorReceptorBiochemistryStereochemistryBiologyTranscription factorLeukemiaRetinoidRexinoidRetinoid-x-receptorStructure-activity-relationshipSmall Molecule TherapeuticSkin NeoplasmsLymphomaTetrahydronaphthalenesCoumaric Acids610leukemia; retinoid; retinoid-x-receptor; rexinoid; small molecule therapeutic; structure-activity-relationshipArticleRetinoidsMedicine and Health SciencesHumansTriglyceridesLiver X Receptors540T-CellLymphoma, T-Cell, CutaneousCutaneousRetinoid X Receptors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene

FAIR Checklist

Authors (25)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)